Publications by authors named "D E Larenas-Linnemann"
Article Synopsis
- CRUSE® is an app designed for people with chronic spontaneous urticaria (CSU) to track their symptoms using visual analogue scales (VASs), aiming to assess the app's effectiveness in measuring disease activity.
- A study analyzed three VASs related to CSU impact on daily life, including one specifically for the severity of urticaria, one for productivity, and a general health measure (EQ-5D), using data from nearly 6,000 patients over many days.
- The results showed that the CRUSE® app's VASs demonstrate strong validity and reliability, with the "VAS urticaria" being most effective in capturing symptom changes, while the minimal important difference (MID) values indicated meaningful changes
Article Synopsis
- - Patient-reported outcome measures (PROMs) are tools that help assess a patient's health at a specific time and are important for personalized healthcare.
- - The paper reviews the use of visual analog scales (VAS) for measuring asthma and allergic rhinitis control, particularly focusing on the MASK-air app, which includes electronic VAS forms.
- - A randomized controlled trial was conducted to validate the electronic VAS, and further evaluations confirmed the effectiveness of VAS questions and additional medication scores for allergic asthma symptoms.
Introduction: Aeroallergen exposure has an intra- and extra-domiciliary component and varies according to climatological zones. Mexico is a large country with a great variety of climates. A previous study (2009) evaluated skin prick test results (SPT) in different regions.
View Article and Find Full Text PDFBackground: Allergic rhinitis (AR) has a substantial socioeconomic impact associated with impaired work productivity.
Objective: To study the impact of AR on work productivity and estimate the corresponding indirect costs for 40 countries.
Methods: We conducted a cross-sectional study using direct patient data from the MASK-air app on users with self-reported AR.
Article Synopsis
- The review evaluates the effectiveness and safety of Janus kinase inhibitors (JAKi) for treating moderate-to-severe atopic dermatitis (AD) in adolescents, highlighting a need for systemic therapies in this age group.
- While JAKi like abrocitinib, baricitinib, and upadacitinib show promise with quick results, baricitinib is ineffective in younger children aged 2 to 10 years.
- Major safety concerns have not emerged in adolescent trials, though there are minor issues like herpes zoster infections and acne, indicating that JAKi could be a valuable option for managing severe AD in young patients.